Is hypomagnesemia associated with using proton pump inhibitors?

Article information

Kidney Res Clin Pract. 2016;35(2):128-129

Publication date (electronic) : 2016 May 12

doi : https://doi.org/10.1016/j.krcp.2016.04.002

Department of Internal Medicine, Hanyang University Guri Hospital, 153 Gyeongchun-ro, Guri, Gyeonggi, 471-701, Korea

To the Editor:

Proton pump inhibitors (PPIs) have been very useful in various gastrointestinal diseases. However, hypomagnesemia was reported in patients taking PPIs, and cross-sectional or retrospective studies for a causal relationship between PPIs and hypomagnesemia were carried out. Until now, this question remains unresolved although a recent meta-analysis study concluded that PPI use may increase the risk of hypomagnesemia [1].

In the past issue of this Journal, Park et al [2] added a controversy to the association between hypomagnesemia and the PPI use. This study was interesting because it was performed on a relatively homogeneous population, who was undergoing percutaneous coronary intervention and whose basal serum magnesium level was normal. The authors made an effort to demonstrate the relationship through various subgroup analyses. However, in this study protocol, the definition of PPI group is not sufficient for detailed history about taking PPIs, as it was uncertain when PPI usage began.

The authors may need to show more data regarding previous PPI usage, serum magnesium level before starting PPIs, and the proportion of patients with previous PPI usage before enrollment. Despite previous PPI usage, some patients in the PPI group may consistently maintain magnesium levels in normal range during the study period. Furthermore, in the previous reports [3], [4], the association between PPI use and a low serum magnesium level was observed among population with higher prevalence of hypomagnesemia, ranging from 6% to 24%. The authors already pointed out a very low incidence of hypomagnesemia in the study population. Unlike calcium balance, magnesium is not readily mobilized from the bone stores. However, if negative magnesium balance continues, the bone stores help to maintain serum magnesium concentration [5]. Therefore, PPI exposure may induce only modest or no significant changes in serum magnesium concentration among patients with normal range of serum magnesium.

References

1. Park C.H., Kim E.H., Roh Y.H., Kim H.Y., Lee S.K.. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One 92014;:e112558. 25394217.

2. Park S.H., Lee S.H., Lee J.S., Shin W.Y., Gil H.W., Yang J.O., Lee E.Y., Hong S.Y.. Changes in serum magnesium concentration after use of a proton pump inhibitor in patients undergoing percutaneous coronary intervention. Kidney Res Clin Pract 342015;:98–102. 26484029.

3. Danziger J., William J.H., Scott D.J., Lee J., Lehman L.W., Mark R.G., Howell M.D., Celi L.A., Mukamal K.J.. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 832013;:692–699. 23325090.

4. Markovits N., Loebstein R., Halkin H., Bialik M., Landes-Westerman J., Lomnicky J., Kurnik D.. The association of proton pump inhibitors and hypomagnesemia in the community setting. J Clin Pharmacol 542014;:889–895. 24771616.

5. Wallach S.. Effects of magnesium on skeletal metabolism. Magnes Trace Elem 91990;:1–14. 2184830.

References

Conflicts of interest

All authors have no conflicts of interest to declare.

Article information Continued

(CC BY-NC-ND, http://creativecommons.org/licenses/by-nc-nd/4.0/) :

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).